Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report

Palmarocchi,Maria  Celeste; Balzarotti Canger,Ruben  Carlo; Saletti,Piercarlo

doi:10.3892/ol.2017.6026

Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report

Authors:
- Maria Celeste Palmarocchi
- Ruben Carlo Balzarotti Canger
- Piercarlo Saletti
View Affiliations

Affiliations: Medical Oncology, Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland, Department of Surgery, Lugano Regional Hospital, 6900 Lugano, Switzerland
Published online on: April 11, 2017 https://doi.org/10.3892/ol.2017.6026
Pages: 4445-4452

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic cancer is the fourth leading cause of cancer mortality and is associated with a poor overall survival even when diagnosed early and considered resectable. Complete surgical removal with negative histological margins is an independent predictor of survival and remains the only potential curative treatment. In borderline resectable pancreatic adenocarcinoma (BRPAC), preoperative systemic therapy may increase resectability and margin‑negative resection rate. There is no current consensus on the optimal chemotherapy regimen for BRPAC. The present case describes a patient with BRPAC who achieved a pathological complete response to neoadjuvant FOLFIRINOX (folinic acid, fluorouracil, irinotecan and oxaliplatin), but early relapse following a pancreaticoduodenectomy without vascular resection, with an uneventful postoperative course, except for a pulmonary embolism.

View Figures

View References

1	Siegel R, Ma JM, Zou ZH and Jemal A: Cancer statistics, 2014. Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar
2	Hidalgo M: Pancreatic cancer. N Engl J Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
3	American Joint Committee on Cancer (AJCC), . TNM staging system. September 6–2013, American Cancer Society;
4	Tamm EP, Silverman PM, Charnsangavej C and Evans DB: Diagnosis, staging, and surveillance of pancreatic cancer. AJR Am J Roentgenol. 180:1311–1323. 2003. View Article : Google Scholar : PubMed/NCBI
5	Varadachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB and Wolff RA: Borderline resectable pancreatic cancer: Definitions, management, and role of preoperative therapy. Ann Surg Oncol. 13:1035–1046. 2006. View Article : Google Scholar : PubMed/NCBI
6	Katz MH, Marsh R, Herman JM, Shi Q, Collison E, Venook AP, Kindler HL, Alberts SR, Philip P, Lowy AM, et al: Borderline resectable pancreatic cancer: Need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 20:2787–2795. 2013. View Article : Google Scholar : PubMed/NCBI
7	Abrams RA, Lowy AM, O'Reilly EM, Wolff RA, Picozzi VJ and Pisters PW: Combined modality treatment of resectable and borderline resectable pancreas cancer: Expert consensus statement. Ann Surg Oncol. 16:1751–1756. 2009. View Article : Google Scholar : PubMed/NCBI
8	Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
9	von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
10	Tempero MA, Malafa MP, Behrman, Benson AB III, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, et al: Pancreatic adenocarcinoma, version 2.2014: Featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 12:1083–1093. 2014. View Article : Google Scholar : PubMed/NCBI
11	Valls C, Andía E, Sanchez A, Fabregat J, Pozuelo O, Quintero JC, Serrano T, Garcia-Borobia F and Jorba R: Dual-phase helical CT of pancreatic adenocarcinoma: Assessment of resectability before surgery. AJR Am J Roentgenol. 178:821–826. 2002. View Article : Google Scholar : PubMed/NCBI
12	Legmann P, Vignaux O, Dousset B, Baraza AJ, Palazzo L, Dumontier I, Coste J, Louvel A, Roseau G, Couturier D and Bonnin A: Pancreatic tumors: Comparison of dual-phase helical CT and endoscopic sonography. AJR Am J Roentgenol. 170:1315–1322. 1998. View Article : Google Scholar : PubMed/NCBI
13	DeWitt J, Devereaux B, Chriswell M, McGreevy K, Howard T, Imperiale TF, Ciaccia D, Lane KA, Maglinte D, Kopecky K, et al: Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann Intern Med. 141:753–763. 2004. View Article : Google Scholar : PubMed/NCBI
14	Michl P, Pauls S and Gress TM: Evidence-based diagnosis and staging of pancreatic cancer. Best Pract Res Clin Gastroenterol. 20:227–251. 2006. View Article : Google Scholar : PubMed/NCBI
15	Kim R, Prithviraj G, Kothari N, Springett G, Malafa M, Hodul P, Kim J, Yue B, Morse B and Mahipal A: PET/CT fusion scan prevents futile laparotomy in early stage pancreatic cancer. Clin Nucl Med. 40:e501–e505. 2015. View Article : Google Scholar : PubMed/NCBI
16	Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, Wang H, Abbruzzese J, Pisters PW, Vauthey JN, et al: Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 118:5749–5756. 2012. View Article : Google Scholar : PubMed/NCBI
17	Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, et al: Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 261:12–17. 2015. View Article : Google Scholar : PubMed/NCBI
18	Hsu CC, Wolfgang CL, Laheru DA, Pawlik TM, Swartz MJ, Winter JM, Robinson R, Edil BH, Narang AK, Choti MA, et al: Early mortality risk score: Identification of poor outcomes following upfront surgery for resectable pancreatic cancer. J Gastrointest Surg. 16:753–761. 2012. View Article : Google Scholar : PubMed/NCBI
19	Tzeng CW, Balachandran A, Ahmad M, Lee JE, Krishnan S, Wang H, Crane CH, Wolff RA, Varadhachary GR, Pisters PW, et al: Serum carbohydrate antigen 19–9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 16:430–438. 2014. View Article : Google Scholar : PubMed/NCBI
20	Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P, et al: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 27:1806–1813. 2009. View Article : Google Scholar : PubMed/NCBI
21	Singh P, Wig JD, Srinivasan R and Radotra BD: A comprehensive examination of Smad4, Smad6 and Smad7 mRNA expression in pancreatic ductal adenocarcinoma. Indian J Cancer. 48:170–174. 2011. View Article : Google Scholar : PubMed/NCBI
22	Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA, Yeo C, Iacobuzio-Donahue C and Goggins M: Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol. 25:319–325. 2007. View Article : Google Scholar : PubMed/NCBI
23	Miyoshi K, Sato N, Ohuchida K, Mizumoto K and Tanaka M: SPARC mRNA expression as a prognostic marker for pancreatic adenocarcinoma patients. Anticancer Res. 30:867–871. 2010.PubMed/NCBI
24	Prenzel KL, Warnecke-Eberz U, Xi H, Brabender J, Baldus SE, Bollschweiler E, Gutschow CA, Hölscher AH and Schneider PM: Significant overexpression of SPARC/osteonectin mRNA in pancreatic cancer compared to cancer of the papilla of Vater. Oncol Rep. 15:1397–1401. 2006.PubMed/NCBI
25	Nagaraju GP, Dontula R, El-Rayes BF and Lakka SS: Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis. Carcinogenesis. 35:967–973. 2014. View Article : Google Scholar : PubMed/NCBI
26	Desai NP, Trieu V, Hwang LY, Wu R, Soon-Shiong P and Gradishar WJ: Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs. 19:899–909. 2008. View Article : Google Scholar : PubMed/NCBI
27	Xiong HQ and Abbruzzese JL: Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol. 29 5 Suppl 14:S31–S37. 2002. View Article : Google Scholar
28	Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG and Korc M: Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 13:565–569. 1993.PubMed/NCBI
29	Hu YC, Komorowski RA, Graewin S, Hostetter G, Kallioniemi OP, Pitt HA and Ahrendt SA: Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer. Clin Cancer Res. 9:4165–4171. 2003.PubMed/NCBI
30	van der Zee JA, van Eijck CH, Hop WC, van Dekken H, Dicheva BM, Seynhaeve AL, Koning GA, Eggermont AM and Ten Hagen TL: Expression and prognostic significance of thymidylate synthase (TS) in pancreatic head and periampullary cancer. Eur J Surg Oncol. 38:1058–1064. 2012. View Article : Google Scholar : PubMed/NCBI
31	Jin K, Luo G, Xiao Z, Liu Z, Liu C, Ji S, Xu J, Liu L, Long J, Ni Q and Yu X: Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer. Drug Des Devel Ther. 9:1247–1255. 2015. View Article : Google Scholar : PubMed/NCBI
32	Ansari D, Gustafsson A and Andersson R: Update on the management of pancreatic cancer: Surgery is not enough. World J Gastroenterol. 21:3157–3165. 2015.PubMed/NCBI
33	Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, et al: Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 26:3496–3502. 2008. View Article : Google Scholar : PubMed/NCBI
34	Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Abdalla E, Wang H, Staerkel GA, et al: Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 26:3487–3495. 2008. View Article : Google Scholar : PubMed/NCBI
35	Cho SW, Tzeng CW, Johnston WC, Cassera MA, Newell PH, Hammill CW, Wolf RF, Aloia TA and Hansen PD: Neoadjuvant radiation therapy and its impact on complications after pancreaticoduodenectomy for pancreatic cancer: Analysis of the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). HPB (Oxford). 16:350–356. 2014. View Article : Google Scholar : PubMed/NCBI
36	Lind PA, Isaksson B, Almström M, Johnsson A, Albiin N, Byström P and Permert J: Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma. Acta Oncol. 47:413–420. 2008. View Article : Google Scholar : PubMed/NCBI
37	Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, Charnsangavej C, Fenoglio CJ and Ames FC: Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 127:1335–1339. 1992. View Article : Google Scholar : PubMed/NCBI
38	Abbott DE, Tzeng CW, Merkow RP, Cantor SB, Chang GJ, Katz MH, Bentrem DJ, Bilimoria KY, Crane CH, Varadhachary GR, et al: The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. Ann Surg Oncol. 20 Suppl 3:S500–S5008. 2013. View Article : Google Scholar : PubMed/NCBI
39	Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH, Wolff RA, et al: Borderline resectable pancreatic cancer: The importance of this emerging stage of disease. J Am Coll Surg. 206:833–848. 2008. View Article : Google Scholar : PubMed/NCBI
40	Chun YS, Milestone BN, Watson JC, Cohen SJ, Burtness B, Engstrom PF, Haluszka O, Tokar JL, Hall MJ, Denlinger CS, et al: Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol. 17:2832–2838. 2010. View Article : Google Scholar : PubMed/NCBI
41	Rose JB, Rocha FG, Alseidi A, Biehl T, Moonka R, Ryan JA, Lin B, Picozzi V and Helton S: Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Ann Surg Oncol. 21:1530–1537. 2014. View Article : Google Scholar : PubMed/NCBI
42	Takahashi H, Ohigashi H, Gotoh K, Marubashi S, Yamada T, Murata M, Ioka T, Uehara H, Yano M and Ishikawa O: Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg. 258:1040–1050. 2013. View Article : Google Scholar : PubMed/NCBI
43	Mahaseth H, Brutcher E, Kauh J, Hawk N, Kim S, Chen Z, Kooby DA, Maithel SK, Landry J and El-Rayes BF: Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas. 42:1311–1315. 2013. View Article : Google Scholar : PubMed/NCBI
44	Boone BA, Steve J, Krasinskas AM, Zureikat AH, Lembersky BC, Gibson MK, Stoller RG, Zeh HJ and Bahary N: Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol. 108:236–241. 2013. View Article : Google Scholar : PubMed/NCBI
45	Gunturu KS, Yao X, Cong X, Thumar JR, Hochster HS, Stein SM and Lacy J: FOLFIRINOX for locally advanced and metastatic pancreatic cancer: Single institution retrospective review of efficacy and toxicity. Med Oncol. 30:3612013. View Article : Google Scholar : PubMed/NCBI
46	Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, Sorscher SM, Suresh R, Lockhart AC, Wang J, Menias C, et al: Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP. 13:497–501. 2012.PubMed/NCBI
47	Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, Narayanan G, Ribeiro A, Portelance L, Merchan JR, et al: A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 12:1992012. View Article : Google Scholar : PubMed/NCBI
48	Tinchon C, Hubmann E, Pichler A, Keil F, Pichler M, Rabl H, Uggowitzer M, Jilek K, Leitner G and Bauernhofer T: Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma. Acta Oncol. 52:1231–1233. 2013. View Article : Google Scholar : PubMed/NCBI
49	Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB and George B: Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: A new treatment paradigm? Oncologist. 19:266–274. 2014. View Article : Google Scholar : PubMed/NCBI
50	Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen JN, Dias LE, et al: FOLFIRINOX in locally advanced pancreatic cancer: The Massachusetts General Hospital Cancer Center experience. Oncologist. 18:543–548. 2013. View Article : Google Scholar : PubMed/NCBI
51	James ES, Yao X, Cong X, Li J, Hahn C, Kaley K, Kortmansky JS, Fischbach NA, Chang BW, Salem RR, et al: Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC). J Clin Oncol. 32 Suppl:e152262014. View Article : Google Scholar
52	Hazariwala R, Landry J, El-Reyes B, et al: Neoadjuvant FOLFIRINOX and radiation therapy improves resectability of pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2 Suppl 1:872013.
53	Vasile E, de Lio N, Cappelli C, et al: Phase II study of neoadjuvant chemotherapy with modified FOLFOXIRI in borderline resectable or unresectable stage III pancreatic cancer. J Clin Oncol. 15(Suppl 1): 312013.
54	Kharofa J, Kelly TR, Ritch PS, George B, Wiebe LA, Thomas JP, Christians KK, Evans DP and Erickson B: 5-FU/leucovorin, irinotecan, oxaliplatin (FOLFIRINOX) induction followed by chemoXRT in borderline resectable pancreatic cancer. J Clin Oncol. 30 Suppl:e146132012.
55	Lowery MA, Yu KH, Adel NG, Apollo AJ, Boyar MS, Caron P, Ilson D, Segal NH, Janjigian YY, Janjigian DR, et al: Activity of front-line FOLFIRINOX (FFX) in stage III/IV pancreatic adenocarcinoma (PC) at Memorial Sloan-Kettering Cancer Center (MSKCC). J Clin Oncol. 30 Suppl:40572012.
56	Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J, Ellison EC, et al: Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 22:1153–1159. 2015. View Article : Google Scholar : PubMed/NCBI
57	Nanda RH, El-Rayes B, Maithel SK and Landry J: Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. J Surg Oncol. 111:1028–1034. 2015. View Article : Google Scholar : PubMed/NCBI
58	Paniccia A, Edil BH, Schulick RD, Byers JT, Meguid C, Gajdos C and McCarter MD: Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: A retrospective cohort study. Medicine (Baltimore). 93:e1982014. View Article : Google Scholar : PubMed/NCBI
59	Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, Malafa MP, Chuong MD and Shridhar R: Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 54:979–985. 2015. View Article : Google Scholar : PubMed/NCBI
60	Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Aitini E and Barni S: Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD): FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: A meta-analytical review of published studies. Pancreas. 44:515–521. 2015. View Article : Google Scholar : PubMed/NCBI
61	Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar : PubMed/NCBI
62	Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, et al: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA. 304:1073–1081. 2010. View Article : Google Scholar : PubMed/NCBI
63	Katz MH, Shi Q, Ahmad SA, Herman JM, de Marsh RW, Collisson EA, Schwartz LH, Martin RC, Conway WC, Truty M, et al: Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101. J Clin Oncol. 33(Suppl): abstr 4008. 2015.
64	Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)-A Single-centre Phase 2a Study of Gemcitabine Plus Nab-paclitaxel for Borderline Unresectable Locally Advanced Pancreatic Cancer. ClinicalTrials.gov Identifier: NCT02124369. 2017.
65	Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, et al: Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Treatment variables and survival duration. Ann Surg Oncol. 8:123–132. 2001. View Article : Google Scholar : PubMed/NCBI
66	Ishikawa O, Ohhigashi H, Teshima T, Chatani M, Inoue T, Tanaka S, Kitamura T, Wada A, Sasaki Y, Imaoka S, et al: Clinical and histopathological appraisal of preoperative irradiation for adenocarcinoma of the pancreatoduodenal region. J Surg Oncol. 40:143–151. 1989. View Article : Google Scholar : PubMed/NCBI
67	Washington K, Berlin J and Branton P: Protocol for the examination of specimens from patients with carcinoma of the exocrine pancreas: Protocol applies to all epithelial tumors of the exocrine pancreas. Endocrine tumors and tumors of the ampulla of Vater are not included Northfield, IL: College of American Pathologists; 2010
68	Oshima M, Okano K, Muraki S, Haba R, Maeba T, Suzuki Y and Yachida S: Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg. 258:336–346. 2013. View Article : Google Scholar : PubMed/NCBI
69	Pendurthi TK, Cooper HS, Young NA, et al: Histopathologic effects of preoperative chemoradiotheraoy on pancreatic carcinoma. Gastroenterology. 110:A1410. 1996.
70	White RR, Xie HB, Gottfried MR, Czito BG, Hurwitz HI, Morse MA, Blobe GC, Paulson EK, Baillie J, Branch MS, et al: Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol. 12:214–221. 2005. View Article : Google Scholar : PubMed/NCBI
71	Sasson AR, Wetherington RW, Hoffman JP, Ross EA, Cooper H, Meropol NJ, Freedman G, Pingpank JF and Eisenberg BL: Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Analysis of histopathology and outcome. Int J Gastrointest Cancer. 34:121–128. 2003. View Article : Google Scholar : PubMed/NCBI
72	Hoffman JP, Weese JL, Solin LJ, Engstrom P, Agarwal P, Barber LW, Guttmann MC, Litwin S, Salazar H and Eisenberg BL: A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg. 169:71–78. 1995. View Article : Google Scholar : PubMed/NCBI
73	Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, et al: Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: Pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 29:2773–2780. 2011. View Article : Google Scholar : PubMed/NCBI
74	García-Aguilar J, de Anda E Hernandez, Sirivongs P, Lee SH, Madoff RD and Rothenberger DA: A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum. 46:298–304. 2003. View Article : Google Scholar : PubMed/NCBI
75	Martin ST, Heneghan HM and Winter DC: Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 99:918–928. 2012. View Article : Google Scholar : PubMed/NCBI
76	Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, Calvo FA, García-Aguilar J, Glynne-Jones R, Haustermans K, et al: Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: A pooled analysis of individual patient data. Lancet Oncol. 11:835–844. 2010. View Article : Google Scholar : PubMed/NCBI
77	Meredith KL, Weber JM, Turaga KK, Siegel EM, McLoughlin J, Hoffe S, Marcovalerio M, Shah N, Kelley S and Karl R: Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol. 17:1159–1167. 2010. View Article : Google Scholar : PubMed/NCBI
78	Pasini F, de Manzoni G, Zanoni A, Grandinetti A, Capirci C, Pavarana M, Tomezzoli A, Rubello D and Cordiano C: Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: A phase 2 study. Cancer. 119:939–945. 2013. View Article : Google Scholar : PubMed/NCBI
79	Rohatgi P, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Roth JA and Ajani JA: Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 104:2365–2372. 2005. View Article : Google Scholar : PubMed/NCBI
80	Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H and Goldberg M: Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 23:4330–4337. 2005. View Article : Google Scholar : PubMed/NCBI
81	Vallböhmer D, Hölscher AH, DeMeester S, DeMeester T, Salo J, Peters J, Lerut T, Swisher SG, Schröder W, Bollschweiler E and Hofstetter W: A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Ann Surg. 252:744–749. 2010. View Article : Google Scholar : PubMed/NCBI
82	Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, et al: Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 25:4414–4422. 2007. View Article : Google Scholar : PubMed/NCBI
83	Adams S, Chakravarthy AB, Donach M, Spicer D, Lymberis S, Singh B, Bauer JA, Hochman T, Goldberg JD, Muggia F, et al: Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: Pathologic response correlates with five-year overall survival. Breast Cancer Res Treat. 124:723–732. 2010. View Article : Google Scholar : PubMed/NCBI
84	Sherman WH, Chu K, Chabot J, Allendorf J, Schrope BA, Hecht E, Jin B, Leung D, Remotti H, Addeo G, et al: Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma. Cancer. 121:673–680. 2015. View Article : Google Scholar : PubMed/NCBI
85	Boone BA, Steve J, Zenati MS, Hogg ME, Singhi AD, Bartlett DL, Zureikat AH, Bahary N and Zeh HJ III: Serum CA 19–9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol. 21:4351–4358. 2014. View Article : Google Scholar : PubMed/NCBI
86	Rajagopalan MS, Heron DE, Wegner RE, Zeh HJ, Bahary N, Krasinskas AM, Lembersky B, Brand R, Moser AJ, Quinn AE and Burton SA: Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer. Radiat Oncol. 8:2542013. View Article : Google Scholar : PubMed/NCBI
87	Lee JL, Kim SC, Kim JH, Lee SS, Kim TW, Park DH, Seo DW, Lee SK, Kim MH, Kim JH, et al: Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery. 152:851–862. 2012. View Article : Google Scholar : PubMed/NCBI
88	Zhao Q, Rashid A, Gong Y, Katz MH, Lee JE, Wolf R, Balachandran A, Varadhachary GR, Pisters PW, Wang H, et al: Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol. 16:29–37. 2012. View Article : Google Scholar : PubMed/NCBI
89	Chatterjee D, Katz MH, Rashid A, Varadhachary GR, Wolff RA, Wang H, Lee JE, Pisters PW, Vauthey JN, Crane C, et al: Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: A predictor for patient outcome. Cancer. 118:3182–3190. 2012. View Article : Google Scholar : PubMed/NCBI
90	Barugola G, Partelli S, Crippa S, Capelli P, D'Onofrio M, Pederzoli P and Falconi M: Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Am J Surg. 203:132–139. 2012. View Article : Google Scholar : PubMed/NCBI
91	Le Scodan R, Mornex F, Partensky C, Mercier C, Valette PJ, Ychou M, Bibeau F and Scoazec JY: Histologic assessment of treatment effect of preoperative chemoradiation in patients presenting with resectable pancreatic adenocarcinoma. Cancer Radiother. 15:97–105. 2011. View Article : Google Scholar : PubMed/NCBI
92	Turrini O, Ychou M, Moureau-Zabotto L, Rouanet P, Giovannini M, Moutardier V, Azria D, Delpero JR and Viret F: Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response. Eur J Surg Oncol. 36:987–92. 2010. View Article : Google Scholar : PubMed/NCBI
93	Magnin V, Moutardier V, Giovannini MH, Lelong B, Giovannini M, Viret F, Monges G, Bardou VJ, Alzieu C and Delpero JR: Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer. Int J Radiat Oncol Biol Phys. 55:1300–1304. 2003. View Article : Google Scholar : PubMed/NCBI
94	Wanebo HJ, Glicksman AS, Vezeridis MP, Clark J, Tibbetts L, Koness RJ and Levy A: Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch Surg. 135:81–88. 2000. View Article : Google Scholar : PubMed/NCBI